Browse Category

Financial Insights News 11 November 2025 - 24 November 2025

XPeng Stock (XPEV) on November 24, 2025: Can a 1 Million EV Milestone Offset Cautious Guidance?

XPeng Stock (XPEV) on November 24, 2025: Can a 1 Million EV Milestone Offset Cautious Guidance?

Published: November 24, 2025 – U.S. markets session preview XPeng stock (NYSE: XPEV) heads into the Monday, November 24, 2025 session in a tricky spot: the Chinese EV maker just delivered blowout third‑quarter results, crossed the 1‑million‑vehicle production milestone, and hit its full‑year 2025 sales target two months early—yet the shares have pulled back after management issued a cautious outlook for the fourth quarter. CnEVPost+2CarNewsChina.com+2 Below is a deep dive into where XPeng stands today, what’s driving XPEV’s price action, and the key catalysts investors will be watching as trading resumes. XPeng stock price today: where XPEV stands before the
TSM Stock: 10 Things to Know Before Monday’s Open on November 24, 2025

TSM Stock: 10 Things to Know Before Monday’s Open on November 24, 2025

Taiwan Semiconductor Manufacturing (NYSE: TSM) goes into the new week sitting at the center of the AI chip boom, geopolitical tension, and a fresh round of headlines about trade secrets and export controls. Here’s what traders and long‑term investors should know before the bell on Monday, November 24, 2025. 1. Where TSM Stock Stands Heading Into Monday TSM’s American depositary receipts (ADRs) closed Friday, November 21, at about $275.06, down roughly 0.9% on the day, after trading in a wide intraday range of $266.82 to $278.69. Over the last 52 weeks, the stock has swung between about $134 and $311,
23 November 2025
Canada Goose (GOOS): Fresh 13F Moves, Buyback Launch, and New Analyst Targets — What Investors Need to Know Today (Nov. 11, 2025)

Canada Goose (GOOS): Fresh 13F Moves, Buyback Launch, and New Analyst Targets — What Investors Need to Know Today (Nov. 11, 2025)

What changed today (Nov. 11, 2025) The most recent developments as of Tuesday, Nov. 11 revolve around post‑earnings positioning and new sell‑side targets. Barclays cut its 12‑month price target to $11 while maintaining Equal‑Weight, citing a more cautious view after last week’s results. UBS raised its target to $12 but stayed Neutral, reflecting improving momentum but limited near‑term conviction. GuruFocus+1 Meanwhile, the company’s renewed normal course issuer bid (NCIB) formally began on Nov. 10, enabling buybacks of up to 4.58M shares over the next 12 months—about 10% of the public float—potentially providing a modest support to per‑share metrics during volatility.
11 November 2025

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

Toyota stock price rises on CEO shake-up and higher profit outlook as buyout deadline nears

7 February 2026
Toyota shares rose 2% to 3,780 yen Friday after the company raised its full-year profit forecast and announced CFO Kenta Kon will replace CEO Koji Sato on April 1. Third-quarter net revenues climbed 6.8% to 38.087 trillion yen, but North America posted a 5.6 billion yen operating loss. Toyota’s U.S. ADRs closed up 2.9%. The tender offer for Toyota Industries shares closes Feb. 12.
Go toTop